Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2019 Oct 15;29(3):785-789. doi: 10.1016/j.celrep.2019.09.089. No abstract available.

2.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047. Erratum in: Cell Rep. 2019 Oct 15;29(3):785-789.

3.

Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment.

Deng W, Lira V, Hudson TE, Lemmens EE, Hanson WG, Flores R, Barajas G, Katibah GE, Desbien AL, Lauer P, Leong ML, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):8179-8184. doi: 10.1073/pnas.1801910115. Epub 2018 Jul 23.

4.

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

5.

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele".

Sivick KE, Surh NH, Desbien AL, Grewal EP, Katibah GE, McWhirter SM, Dubensky TW Jr.

J Immunol. 2017 Jun 1;198(11):4183-4185. doi: 10.4049/jimmunol.1700294. No abstract available.

6.

A structure-function approach to optimizing TLR4 ligands for human vaccines.

Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Ireton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG.

Clin Transl Immunology. 2016 Nov 2;5(11):e108. eCollection 2016 Nov.

7.

IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, Duthie MS, Fox CB, Reed SG, Orr MT.

J Immunol. 2016 Dec 1;197(11):4351-4359. Epub 2016 Oct 28.

9.

Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Dubois Cauwelaert N, Baldwin SL, Orr MT, Desbien AL, Gage E, Hofmeyer KA, Coler RN.

Eur J Immunol. 2016 Dec;46(12):2719-2729. doi: 10.1002/eji.201646399. Epub 2016 Nov 9.

10.

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.

Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT.

PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. eCollection 2016.

11.

Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.

Desbien AL, Reed SJ, Bailor HR, Dubois Cauwelaert N, Laurance JD, Orr MT, Fox CB, Carter D, Reed SG, Duthie MS.

Eur J Immunol. 2015 Feb;45(2):407-17. doi: 10.1002/eji.201444543. Epub 2014 Dec 3.

12.

Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.

Orr MT, Kramer RM, Barnes L 5th, Dowling QM, Desbien AL, Beebe EA, Laurance JD, Fox CB, Reed SG, Coler RN, Vedvick TS.

J Control Release. 2014 Mar 10;177:20-6. doi: 10.1016/j.jconrel.2013.12.025. Epub 2013 Dec 29.

13.

TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses.

Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, Coler RN, Reed SG.

Vaccine. 2013 Dec 2;31(49):5848-55. doi: 10.1016/j.vaccine.2013.09.069. Epub 2013 Oct 10.

PMID:
24120675
14.

Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses.

Desbien AL, Van Hoeven N, Reed SJ, Casey AC, Laurance JD, Baldwin SL, Duthie MS, Reed SG, Carter D.

Biotechniques. 2013 Jun;54(6):345-8. doi: 10.2144/000114041.

15.

MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Orr MT, Duthie MS, Windish HP, Lucas EA, Guderian JA, Hudson TE, Shaverdian N, O'Donnell J, Desbien AL, Reed SG, Coler RN.

Eur J Immunol. 2013 Sep;43(9):2398-408. doi: 10.1002/eji.201243124. Epub 2013 Jul 3.

16.

Targeting TLRs expands the antibody repertoire in response to a malaria vaccine.

Wiley SR, Raman VS, Desbien A, Bailor HR, Bhardwaj R, Shakri AR, Reed SG, Chitnis CE, Carter D.

Sci Transl Med. 2011 Jul 27;3(93):93ra69. doi: 10.1126/scitranslmed.3002135.

17.

The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim.

Desbien AL, Kappler JW, Marrack P.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5663-8. doi: 10.1073/pnas.0901036106. Epub 2009 Mar 17.

18.

Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.

Speelmon EC, Livingston-Rosanoff D, Desbien AL, Lee J, Wick WD, Hladik F, McElrath MJ.

AIDS Res Hum Retroviruses. 2008 Nov;24(11):1415-27. doi: 10.1089/aid.2007.0256.

19.

Kidney function and progression of carotid intima-media thickness in a community study.

Desbien AM, Chonchol M, Gnahn H, Sander D.

Am J Kidney Dis. 2008 Apr;51(4):584-93. doi: 10.1053/j.ajkd.2007.11.026. Epub 2008 Mar 3.

PMID:
18371534
20.

Chronic kidney disease is associated with angiographic coronary artery disease.

Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR.

Am J Nephrol. 2008;28(2):354-60. Epub 2007 Nov 29.

PMID:
18046083
21.

Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells.

Hladik F, Desbien A, Lang J, Wang L, Ding Y, Holte S, Wilson A, Xu Y, Moerbe M, Schmechel S, McElrath MJ.

J Immunol. 2003 Sep 1;171(5):2671-83.

22.

Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons.

Schmechel SC, Russell N, Hladik F, Lang J, Wilson A, Ha R, Desbien A, McElrath MJ.

Immunol Lett. 2001 Nov 1;79(1-2):21-7.

PMID:
11595286

Supplemental Content

Loading ...
Support Center